---
document_datetime: 2023-11-09 19:33:27
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rukobia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: rukobia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.1354267
conversion_datetime: 2025-12-22 10:27:03.600269
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rukobia

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                        |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011              | Update of section 5.1 of the SmPC in order to update cross-resistance information based on results from virology study aimed at further characterization of HIV-1 gp120 amino acid polymorphism E202. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 14/09/2023                          |                                             | SmPC                             | There was no evidence of cross-resistance to representative agents from other antiretroviral (ARV) classes. Temsavir retained wild-type activity against viruses resistant to the INSTI raltegravir; the NNRTIs rilpivirine and efavirenz; the NRTIs abacavir, lamivudine, tenofovir, zidovudine and the PIs atazanavir and darunavir. Additionally, abacavir, |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data   |            |     | tenofovir, efavirenz, rilpivirine, atazanavir, darunavir and raltegravir retained activity against site-directed mutant viruses with reduced temsavir susceptibility (S375M, M426L, or M426L plus M475I). No cross-resistance was observed between temsavir and maraviroc or enfuvirtide. Temsavir was active against viruses with resistance to enfuvirtide. Some CCR5-tropic, maraviroc-resistant, viruses showed reduced susceptibility to temsavir, however, there was no absolute correlation between maraviroc resistance and reduced sensitivity to temsavir. Maraviroc and enfuvirtide retained activity against clinical envelopes from the Phase IIa study (206267) that had reduced susceptibility to temsavir and contained S375H, M426L, or M426L plus M475I substitutions. Temsavir was active against several ibalizumab-resistant viruses. Ibalizumab retained activity against site-directed mutant viruses that had reduced susceptibility to temsavir (S375M, M426L, or M426L plus M475I). HIV-1 gp120 E202 was identified as a rare treatment-emergent substitution in BRIGHTE that can reduce susceptibility to temsavir, and, depending on the sequence context of the envelope, may also result in reduced susceptibility to ibalizumab. For more information, please refer to the Summary of   |
|---------------------|----------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10911 /202302 | Periodic Safety Update EU Single assessment - fostemsavir      | 31/08/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10911 /202208 | Periodic Safety Update EU Single assessment - fostemsavir      | 16/03/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10911 /202202   | Periodic Safety Update EU Single assessment - fostemsavir                                                                                                                                                                                                                                                                                                                               | 01/09/2022   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IG/1531               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                          | 19/08/2022   | 04/08/2023 | SmPC and PL            |                                     |
| PSUSA/10911 /202108   | Periodic Safety Update EU Single assessment - fostemsavir                                                                                                                                                                                                                                                                                                                               | 10/03/2022   | n/a        |                        | PRAC Recommendation - maintenance   |
| IA/0005/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 15/10/2021   | n/a        |                        |                                     |
| IB/0003               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                          | 05/07/2021   | 24/03/2022 | SmPC and PL            |                                     |
| IB/0004               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                              | 28/06/2021   | n/a        |                        |                                     |
| IB/0002               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                     | 10/03/2021   | 24/03/2022 | SmPC, Labelling and PL |                                     |